EXTON, Pa., Aug. 1 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that it will release its earnings results for its fourth quarter and fiscal year ended June 30, 2006, before 8:00 A.M. Eastern Time on Monday, August 21, 2006.
Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Monday, August 21, 2006 at 9:00 A.M. Eastern Time.
To participate in the teleconference call, dial 1-612-332-1025. The teleconference call will also be available for replay starting Monday, August 21, 2006 at 12:30 P.M. Eastern Time through Monday, August 28, 2006 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 838277.
Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com/. To listen to the live teleconference call, please go to the http://www.kenseynash.com/ website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com/ website and may be accessed following the teleconference.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also commercialized a series of innovative embolic protection and thrombectomy products through its own direct endovascular sales force. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Cautionary Note Regarding Forward-Looking Statements. This press release contains forward-looking statements that reflect Kensey Nash's current expectations about its prospects and opportunities, including, without limitation, expectations regarding Kensey Nash's TriActiv(R) System and its other endovascular products. Kensey Nash has tried to identify these forward- looking statements by using words such as "plans," "believes," "expects," "anticipates," "will," "should" or similar expressions, but these words are not the exclusive means for identifying such statements. Kensey Nash cautions that a number of risks, uncertainties, and other important factors could cause Kensey Nash's actual results, performance or achievements to differ materially from those expressed in, or implied by, these forward-looking statements, including, without limitation, the ability of Kensey Nash to obtain necessary regulatory approvals for other versions of the TriActiv(R) System and other new endovascular products, the ability of Kensey Nash to successfully market the TriActiv(R) System and other endovascular products, and competition from other technologies in the embolic protection market. For a more detailed discussion of these and other factors, please see Kensey Nash's filings with the Securities and Exchange Commission. Except as expressly required by the federal securities laws, Kensey Nash undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
